Categories: All postsCannabis

Plus Products could be a leader in edibles, says PI Financial

California-based branded cannabis company Plus Products (Plus Products Stock Quote, Chart CSE:PLUS) received a coverage launch from PI Financial Wednesday, with analyst Jason Zandberg saying Plus has a legitimate chance at becoming one of the few nationally recognized cannabis edibles brands.

Plus was ranked the 50th best-selling brand among hundreds of legal products in California when it received its manufacturing license in December of 2017 but has since become the number one edibles brand in the state, one of the largest and the most competitive pot markets in the world.

Zandberg says California’s rollout of adult-use cannabis has not been a smooth one.

“Although the $2.5 billion in 2018 sales makes it the largest market in the US, the market has been held back by structural challenges including licensing and zoning challenges, a pervasive black market. We expect many of these market challenges to be eliminated in the near future which should expand the market size significantly,” Zandberg writes.

Plus’s products include THC and CBD infused gummies sold in over 300 licensed dispensaries in California, with plans to introduce new baked goods and mints over the summer of 2019. The company recently entered into the Nevada market, after which Zandberg expects Plus to expand into other key markets including Arizona, Florida, Illinois and Michigan.

“We believe that PLUS Products represent a cannabis company that has established itself in California and has a great chance to become one of the few national recognized cannabis brands over time,” says Zandberg.

The analyst launches his coverage calling for fiscal 2019 revenue and EBITDA of $23.5 million and negative $3.2 million, respectively, and fiscal 2020 revenue and EBITDA of $72.8 million and $13.9 million, respectively. (All figures in US dollars unless otherwise noted.)

Zandberg is giving Plus a “Buy” rating with a “Speculative” risk rating and a $7.75 target, which represents a 12-month return of 64.9 per cent at the time of publication.

We Hate Paywalls Too!

At Cantech Letter we prize independent journalism like you do. And we don't care for paywalls and popups and all that noise That's why we need your support. If you value getting your daily information from the experts, won't you help us? No donation is too small.

Make a one-time or recurring donation

Tagged with: plus
Jayson MacLean

Jayson is a writer, researcher and educator with a PhD in political philosophy from the University of Ottawa. His interests range from bioethics and innovations in the health sciences to governance, social justice and the history of ideas.

Recent Posts

Is Peloton Stock a Buy? (May, 2024)

Following news of a restructuring, Roth MKM analyst George Kelly has chopped his price target on Peloton (Peloton Stock Quote,… [Read More]

3 days ago

Is Ascend Wellness stock a buy?

Ahead of the company's first quarter results, Beacon analyst Russell Stanley thinks Ascend Wellness (Ascend Wellness Stock Quote, Chart, News,… [Read More]

3 days ago

Paradigm chops price target on Snipp Interactive

Following the company's fourth quarter results, Paradigm Capital analyst Daniel Rosenberg has cut his price target on Snipp Interactive (Snipp… [Read More]

3 days ago

It’s time to buy cannabis stocks, this analyst says

A major development came down the pipe this week at the U.S. Drug Enforcement Agency has reportedly decided to reschedule… [Read More]

4 days ago

Is Generac stock a buy?

Following the company's first quarter results, Roth MKM analyst Chip Moore remains neutral on Generac Holdings (Generac Holdings Stock Quote,… [Read More]

4 days ago

Bombardier is a buy, Desjardins says (May, 2024)

The stock has climbed slowly but surely since last October. But is there still money to be made on Bombardier?… [Read More]

4 days ago